Hainan Zhonghe Pharmaceutical

Hainan Zhonghe Pharmaceutical is a leading Chinese biopharmaceutical company specializing in the development, production, and marketing of peptide drugs. Founded in 1995 and headquartered in Haikou, Hainan, it was the first high-tech enterprise in China dedicated to synthetic peptide therapeutics and has grown into one of the largest peptide drug production bases in Asia. The company's portfolio features several well-established products, including immunomodulators like Thymopentin (Hexin) and Thymalfasin (Heri), as well as treatments for gastrointestinal and endocrine disorders such as Somatostatin and Octreotide. Zhonghe utilizes advanced solid-phase peptide synthesis technology and maintains GMP-certified facilities that serve both domestic and international markets. As a pioneer in the Chinese peptide industry, the company continues to expand its pipeline into metabolic and cardiovascular therapeutic areas.